Drug intervention as an emerging concept for secondary prevention in patients with coronary disease.

[1]  Yoshio Kobayashi,et al.  Contemporary coronary drug-eluting and coated stents: an updated mini-review (2023) , 2023, Cardiovascular intervention and therapeutics.

[2]  L. Räber,et al.  Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy. , 2023, Journal of the American College of Cardiology.

[3]  L. Räber,et al.  Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. , 2022, JAMA.

[4]  K. Node,et al.  Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives , 2022, Cardiovascular Intervention and Therapeutics.

[5]  Hong Wang,et al.  Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. , 2022, JACC. Cardiovascular imaging.

[6]  J. Granada,et al.  Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial. , 2021, European heart journal.

[7]  M. Kawasaki,et al.  Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study. , 2021, European heart journal cardiovascular Imaging.

[8]  M. Okubo,et al.  Effect of PCSK-9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque Assessed by Near-Infrared Spectroscopy. , 2020, JACC. Cardiovascular imaging.

[9]  T. Ishimitsu,et al.  Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. , 2020, Journal of cardiology.

[10]  L. Räber,et al.  Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS). , 2019, Journal of the American College of Cardiology.

[11]  Eloisa Arbustini,et al.  Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study. , 2019, European heart journal.

[12]  K. Meguro,et al.  Incidence, factors, and clinical significance of cholesterol crystals in coronary plaque: An optical coherence tomography study. , 2019, Atherosclerosis.

[13]  J. Fujimoto,et al.  Calcified Plaques in Patients With Acute Coronary Syndromes. , 2019, JACC. Cardiovascular interventions.

[14]  Deepak L. Bhatt,et al.  Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. , 2019, Journal of the American College of Cardiology.

[15]  P. Libby,et al.  Nonculprit Plaque Characteristics in Patients With Acute Coronary Syndrome Caused by Plaque Erosion vs Plaque Rupture: A 3-Vessel Optical Coherence Tomography Study , 2018, JAMA cardiology.

[16]  T. Akasaka,et al.  Effect of Early Pitavastatin Therapy on Coronary Fibrous-Cap Thickness Assessed by Optical Coherence Tomography in Patients With Acute Coronary Syndrome: The ESCORT Study. , 2017, JACC. Cardiovascular imaging.

[17]  J. Fujimoto,et al.  Clinical Significance of Lipid-Rich Plaque Detected by Optical Coherence Tomography: A 4-Year Follow-Up Study. , 2017, Journal of the American College of Cardiology.

[18]  W. Koenig,et al.  Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. , 2016, JAMA.

[19]  Hang Lee,et al.  Comparison of Intensive Versus Moderate Lipid-Lowering Therapy on Fibrous Cap and Atheroma Volume of Coronary Lipid-Rich Plaque Using Serial Optical Coherence Tomography and Intravascular Ultrasound Imaging. , 2016, The American journal of cardiology.

[20]  T. Kakuta,et al.  Plaque morphologies and the clinical prognosis of acute coronary syndrome caused by lesions with intact fibrous cap diagnosed by optical coherence tomography. , 2016, International journal of cardiology.

[21]  K. Sakamoto,et al.  Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. , 2015, Journal of the American College of Cardiology.

[22]  Marco Roffi,et al.  Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. , 2015, European heart journal.

[23]  T. Akasaka,et al.  Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. , 2014, Journal of the American College of Cardiology.

[24]  M. Kimura,et al.  Impact on optical coherence tomographic coronary findings of fluvastatin alone versus fluvastatin + ezetimibe. , 2014, The American journal of cardiology.

[25]  Bo Yu,et al.  In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. , 2013, Journal of the American College of Cardiology.

[26]  Samin K. Sharma,et al.  Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). , 2013, Journal of the American College of Cardiology.

[27]  R. Yeh,et al.  Comparison of nonculprit coronary plaque characteristics between patients with and without diabetes: a 3-vessel optical coherence tomography study. , 2012, JACC. Cardiovascular interventions.

[28]  P. Serruys,et al.  Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. , 2012, JACC. Cardiovascular imaging.

[29]  P. Serruys,et al.  Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. , 2012, JACC. Cardiovascular imaging.

[30]  P. Serruys,et al.  Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. , 2012, JACC. Cardiovascular imaging.

[31]  Hiroto Tsujioka,et al.  Multiple coronary lesion instability in patients with acute myocardial infarction as determined by optical coherence tomography. , 2010, The American journal of cardiology.

[32]  Katsumi Miyauchi,et al.  Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin , 2009, Journal of the American College of Cardiology.

[33]  A. Hirayama,et al.  Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound. , 2009, JACC. Cardiovascular interventions.

[34]  Seung‐Jung Park,et al.  A three-vessel virtual histology intravascular ultrasound analysis of frequency and distribution of thin-cap fibroatheromas in patients with acute coronary syndrome or stable angina pectoris. , 2008, The American journal of cardiology.

[35]  P. Fitzgerald,et al.  Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study. , 2005, American heart journal.

[36]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[37]  OUP accepted manuscript , 2021, European Heart Journal - Cardiovascular Imaging.

[38]  Yoshihiko Saito,et al.  Thin-cap fibroatheroma and microchannel findings in optical coherence tomography correlate with subsequent progression of coronary atheromatous plaques. , 2012, European heart journal.

[39]  M. Clearfield.  Effect of very high intensity statin therapy on regression of coronary atherosclerosis. , 2007, Current atherosclerosis reports.